Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARIA V GARCIA PALLAS

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1720019912
CMS profile
383636
Location
CAGUAS, PR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$13,834.70

141 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARIA V GARCIA PALLAS

NPI 1720019912 · CMS profile ID 383636

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CAGUAS, PR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1720019912?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARIA V GARCIA PALLAS, NPI 1720019912, CMS profile ID 383636. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720019912?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MARIA V GARCIA PALLAS, NPI 1720019912, CMS profile ID 383636. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720019912?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MARIA V GARCIA PALLAS, NPI 1720019912, CMS profile ID 383636, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1720019912?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

141 matching records · $13,834.70 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 141 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–141 of 141.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Adaptive Biotechnologies Corporation $19.7904/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150263261 CMS
Amgen Inc. $17.6604/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111580704 CMS
ABBVIE INC. $14.0304/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103774831 CMS
Astellas Pharma US Inc $18.9504/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139324642 CMS
GENZYME CORPORATION $25.0004/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139779070 CMS
PBG PUERTO RICO LLC $23.9503/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131312785 CMS
ARRAY BIOPHARMA INC $15.5903/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131419678 CMS
PBG PUERTO RICO LLC $22.7403/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131295254 CMS
Eli Lilly Export S.A. Puerto Rico Branch $23.8803/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135154736 CMS
Janssen Pharmaceuticals, Inc $24.5303/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078167561 CMS
E.R. Squibb & Sons, L.L.C. $7.6703/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101260367 CMS
Merck Sharp & Dohme LLC $11.4803/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141624798 CMS
PBG PUERTO RICO LLC $25.0003/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131295250 CMS
Merck Sharp & Dohme LLC $16.3603/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141845073 CMS
E.R. Squibb & Sons, L.L.C. $22.9303/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101260355 CMS
Exelixis Inc. $14.5002/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138561460 CMS
SpringWorks Therapeutics, Inc. $19.1302/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085804539 CMS
Tempus AI, Inc $20.6002/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150164960 CMS
Merck Sharp & Dohme LLC $87.4502/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141741745 CMS
AstraZeneca Pharmaceuticals LP $22.9502/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105482185 CMS
Amgen Inc. $22.7402/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117257685 CMS
Merck Sharp & Dohme LLC $19.6202/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141624900 CMS
PBG PUERTO RICO LLC $20.8102/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131188634 CMS
PFIZER INC. $24.5302/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131289073 CMS
E.R. Squibb & Sons, L.L.C. $22.4502/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101260349 CMS
PBG PUERTO RICO LLC $22.9502/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131421849 CMS
Amgen Inc. $23.5902/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117257683 CMS
Bayer Puerto Rico Inc. $25.0001/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086223728 CMS
Verity Pharmaceuticals Inc. $20.9601/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080605402 CMS
AstraZeneca Pharmaceuticals LP $22.0001/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105859162 CMS
PBG PUERTO RICO LLC $8.2301/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131335024 CMS
SOBI, INC $19.7401/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141436643 CMS
Janssen Pharmaceuticals, Inc $22.4501/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078167717 CMS
Janssen Pharmaceuticals, Inc $25.0001/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078167683 CMS
Genentech USA, Inc. $19.2601/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133060663 CMS
Tempus AI, Inc $14.7101/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150164958 CMS
Genentech USA, Inc. $19.9801/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133060642 CMS
Janssen Pharmaceuticals, Inc $3.8001/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078167665 CMS
Exelixis Inc. $18.7601/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138561458 CMS
AstraZeneca Pharmaceuticals LP $20.0001/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104640931 CMS
E.R. Squibb & Sons, L.L.C. $2,106.0001/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101260345 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $15,789.80 111
PY2020 $3,776.72 39
PY2021 $3,330.67 89
PY2022 $13,297.02 109
PY2023 $11,390.12 127
PY2024 $13,834.70 141
PY2025 $11,050.98 127

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,491,708.51 206
PY2024 Principal investigator $226,882.82 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

206 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $25,129.00 12/29/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) No dispute reported 06/30/2026 1185540427
Principal investigator 1 ABBVIE INC. $325.00 12/18/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202531182
Principal investigator 1 ABBVIE INC. $10,290.80 12/18/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202531194
Principal investigator 1 PFIZER INC. $369.00 12/15/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC Hosp Oncologico PR Medical Ctr
A GLOBAL PHASE 23 INTERVENTIONAL STUDY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228715541
Principal investigator 1 PFIZER INC. $123.60 12/15/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC Hosp Oncologico PR Medical Ctr
A GLOBAL PHASE 23 INTERVENTIONAL STUDY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228716055
Principal investigator 1 AstraZeneca Pharmaceuticals LP $25,129.00 12/12/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non small Cell Lung Cancer Whose Tumors Express PDL1 ARTEMIDE Lung03 No dispute reported 06/30/2026 1185540425
Principal investigator 1 ABBVIE INC. $4,229.66 12/04/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202527452
Principal investigator 1 ABBVIE INC. $5,754.88 12/04/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202527454
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,211.44 11/26/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223288777
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,755.00 11/13/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813119
Principal investigator 1 ABBVIE INC. $650.00 11/06/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202523271
Principal investigator 1 ABBVIE INC. $750.00 11/06/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202523273
Principal investigator 1 ABBVIE INC. $10,398.12 11/06/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202523275
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $74,998.14 11/06/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials, Llc
A study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1235994786
Principal investigator 1 ABBVIE INC. $2,114.83 11/05/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202521843
Principal investigator 1 ABBVIE INC. $10,961.66 11/05/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202521915
Principal investigator 1 ABBVIE INC. $1,050.00 10/28/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202518793
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $220.61 10/27/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220997270
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $69.96 10/27/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220997272
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $119.88 10/27/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220997274
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $73.00 10/27/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220997276
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $19.60 10/27/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220997278
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $11.50 10/27/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220997280
Principal investigator 1 ABBVIE INC. $350.00 10/24/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518483
Principal investigator 1 ABBVIE INC. $350.00 10/24/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518485
Principal investigator 1 ABBVIE INC. $4,749.00 10/23/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202518341
Principal investigator 1 ABBVIE INC. $1,050.00 10/23/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202518343
Principal investigator 1 ABBVIE INC. $1,870.00 10/22/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517917
Principal investigator 1 ABBVIE INC. $1,988.00 10/22/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517919
Principal investigator 1 ABBVIE INC. $891.00 10/22/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517921
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,558.02 10/16/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223287045
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,571.00 10/15/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813115
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,126.00 10/15/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813117
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,286.00 10/10/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813107
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,286.00 10/10/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813109
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,800.00 10/10/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813111
Principal investigator 1 ABBVIE INC. $10,290.80 10/09/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202515313
Principal investigator 1 ABBVIE INC. $5,021.83 10/09/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202515537
Principal investigator 1 ABBVIE INC. $5,341.95 10/08/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202513533
Principal investigator 1 AstraZeneca Pharmaceuticals LP $25,129.00 10/08/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
A Phase III, Open-label, Randomized Study of Osimertinib with or without Datopotamab deruxtecan (Dato-DXd), as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer No dispute reported 06/30/2026 1185540421
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,447.55 10/06/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813113
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,432.43 10/02/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223286163
Principal investigator 1 ABBVIE INC. $9,125.93 09/23/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202511894
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,194.00 09/10/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813105
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,413.10 09/09/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813103
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,883.75 09/08/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223285165
Principal investigator 1 ABBVIE INC. $10,189.29 09/04/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202509318
Principal investigator 1 ABBVIE INC. $11,157.41 09/04/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202509320
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,600.16 09/04/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223285121
Principal investigator 1 Celgene Corporation $64,505.42 09/03/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials Llc
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1222306383
Principal investigator 1 Merck Sharp & Dohme LLC $3,733.62 08/31/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials - Ciudadela
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemoth No dispute reported 06/30/2026 1232923446
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,706.55 08/20/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813101
Principal investigator 1 ABBVIE INC. $5,939.83 08/06/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202502825
Principal investigator 1 ABBVIE INC. $2,805.30 08/06/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202502827
Principal investigator 1 ABBVIE INC. $20,955.65 08/06/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202502867
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,286.00 08/01/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813097
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,286.00 08/01/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813099
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,127.60 08/01/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223283311
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $891.00 08/01/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223283313
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,468.80 08/01/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223283315
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $23,311.99 07/31/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223283301
Principal investigator 1 ABBVIE INC. $350.00 07/18/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498842
Principal investigator 1 ABBVIE INC. $1,870.00 07/18/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498844
Principal investigator 1 ABBVIE INC. $350.00 07/18/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498856
Principal investigator 1 ABBVIE INC. $1,988.00 07/18/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498858
Principal investigator 1 ABBVIE INC. $891.00 07/18/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498878
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,172.00 07/17/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813095
Principal investigator 1 ABBVIE INC. $10,398.12 07/16/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202498446
Principal investigator 1 ABBVIE INC. $750.00 07/16/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202498452
Principal investigator 1 ABBVIE INC. $350.00 07/16/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202498454
Principal investigator 1 ABBVIE INC. $25,508.67 07/16/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202498460
Principal investigator 1 ABBVIE INC. $10,728.20 07/15/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202498298
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,672.00 07/15/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813091
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,344.00 07/15/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813093
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $19,436.27 07/15/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223282608
Principal investigator 1 ABBVIE INC. $2,017.51 07/10/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202497740
Principal investigator 1 ABBVIE INC. $1,366.20 07/10/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202497748
Principal investigator 1 ABBVIE INC. $4,772.86 07/10/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202497750
Principal investigator 1 ABBVIE INC. $3,806.33 07/10/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202497752
Principal investigator 1 ABBVIE INC. $5,170.50 07/08/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202497442
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,413.10 07/08/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813089
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $837.68 07/07/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223282258
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $607.50 07/07/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223282260
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $607.50 07/07/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223282262
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $202.50 07/07/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223282264
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,618.50 07/03/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223282212
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,571.20 07/03/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223282214
Principal investigator 1 ABBVIE INC. $21,619.85 07/02/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202496453
Principal investigator 1 ABBVIE INC. $5,587.48 07/02/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202496455
Principal investigator 1 ABBVIE INC. $8,645.23 07/02/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202496461
Principal investigator 1 ABBVIE INC. $5,817.15 06/30/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493669
Principal investigator 1 ABBVIE INC. $573.75 06/30/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493671
Principal investigator 1 ABBVIE INC. $789.75 06/30/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493673
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $576.98 06/24/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220997282
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $159.84 06/24/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220997284
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $146.00 06/24/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220997286
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $17.52 06/24/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220997288
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,706.55 06/09/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813087
Principal investigator 1 ABBVIE INC. $9,841.09 06/03/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202489253
Principal investigator 1 ABBVIE INC. $14,121.84 06/03/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202489255
Principal investigator 1 ABBVIE INC. $8,467.20 06/03/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202489257
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $33,731.96 05/29/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223280508
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $122.85 05/28/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223280388
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,724.97 05/28/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223280390
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $303.75 05/28/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223280392
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,635.87 05/27/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223280312
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,618.50 05/27/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223280314
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $162.00 05/27/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223280316
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,268.00 05/27/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223280318
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,398.30 05/27/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223280320
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,755.67 05/27/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223280322
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $506.25 05/27/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223280324
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $506.25 05/27/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223280326
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $33,923.00 05/13/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813083
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,516.00 05/13/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813085
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,507.60 05/12/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813081
Principal investigator 1 ABBVIE INC. $13,416.89 05/08/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202484255
Principal investigator 1 ABBVIE INC. $5,106.81 05/07/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202482607
Principal investigator 1 ABBVIE INC. $39,361.04 05/07/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202482615
Principal investigator 1 ABBVIE INC. $11,576.25 05/07/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202484015
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $35,467.41 05/07/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223278942
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,890.00 05/02/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223278818
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,849.20 05/02/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223278820
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,100.00 05/02/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223278822
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $27,963.10 04/30/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223278708
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,100.00 04/30/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223278710
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $700.00 04/30/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223278712
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $700.00 04/30/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223278714
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $700.00 04/30/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223278716
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $700.00 04/30/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223278718
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $16.97 04/23/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220997266
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $11.66 04/23/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220997268
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,227.50 04/17/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223278186
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,586.00 04/17/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223278188
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,618.50 04/17/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223278190
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,618.50 04/17/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223278192
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,403.43 04/17/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223278194
Principal investigator 1 Celgene Corporation $37,070.00 04/09/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials Llc
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). No dispute reported 06/30/2026 1222306479
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27,013.00 04/07/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813077
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $925.00 04/07/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813079
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,794.75 04/04/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813067
Principal investigator 1 ABBVIE INC. $16,783.42 04/03/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202470632
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,738.16 03/28/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223277119
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,980.65 03/26/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223277021
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,212.00 03/25/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223276989
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,980.65 03/25/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223276991
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,140.76 03/25/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223276993
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,620.00 03/25/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223276995
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $405.00 03/25/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223276997
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,047.30 03/25/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223277001
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,738.16 03/25/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223277003
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,140.76 03/25/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223277005
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $57,749.55 03/18/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813075
Principal investigator 1 ABBVIE INC. $22,884.18 03/07/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202459332
Principal investigator 1 ABBVIE INC. $23,983.00 03/07/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
M24-536 - A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202459467
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $31,545.66 03/03/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223275719
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $356.37 02/25/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220997254
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $209.88 02/25/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220997256
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $179.82 02/25/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220997258
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $109.50 02/25/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220997260
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8.40 02/25/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220997262
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $24.00 02/25/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220997264
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $350.00 02/13/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813073
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $25,065.00 02/11/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223275035
Principal investigator 1 ABBVIE INC. $10,656.39 02/06/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY
M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202446880
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,263.00 02/06/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813071
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,993.00 02/05/2025 Non-covered Recipient Entity
Pan American Center for Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813069
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,685.51 02/05/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223274775
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,676.38 02/05/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223274777
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $570.38 02/04/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223274723
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,106.00 02/04/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223274725
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,106.00 02/04/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223274727
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,106.00 02/04/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223274729
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,571.20 02/04/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223274731
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,888.99 02/04/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223274733
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,923.75 02/04/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223274735
Principal investigator 1 Genmab A/S $22,000.00 02/03/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235932877
Principal investigator 1 Genmab A/S $2,500.00 02/03/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235932880
Principal investigator 1 Genmab A/S $1,538.00 02/03/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235932884
Principal investigator 1 ABBVIE INC. $650.00 01/29/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442278
Principal investigator 1 ABBVIE INC. $51.00 01/29/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442283
Principal investigator 1 ABBVIE INC. $51.00 01/29/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442286
Principal investigator 1 ABBVIE INC. $51.00 01/29/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442290
Principal investigator 1 ABBVIE INC. $51.00 01/29/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442393
Principal investigator 1 AstraZeneca UK Limited $8,525.00 01/29/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
An Observational Multi-center Study to Evaluate Real-World Treatment Outcomes of Durvalumab-based Regimens in Hepatobiliary Cancers No dispute reported 06/30/2026 1185540423
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $169.70 01/27/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220997246
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $93.28 01/27/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220997248
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $59.94 01/27/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220997250
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3.50 01/27/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials LLC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220997252
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,516.18 01/27/2025 Non-covered Recipient Entity
Pan American Center For Oncology Trials - Ciudadela
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). No dispute reported 06/30/2026 1235994794
Principal investigator 1 ABBVIE INC. $403.99 01/22/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440759
Principal investigator 1 ABBVIE INC. $103.95 01/22/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440763
Principal investigator 1 ABBVIE INC. $403.99 01/22/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440767
Principal investigator 1 ABBVIE INC. $2,894.54 01/22/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440771
Principal investigator 1 ABBVIE INC. $2,894.54 01/22/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440775
Principal investigator 1 ABBVIE INC. $379.35 01/22/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440780
Principal investigator 1 ABBVIE INC. $403.99 01/22/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440784
Principal investigator 1 ABBVIE INC. $444.15 01/22/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440787
Principal investigator 1 ABBVIE INC. $109.35 01/22/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440800
Principal investigator 1 ABBVIE INC. $202.50 01/22/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440803
Principal investigator 1 ABBVIE INC. $287.55 01/22/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440808
Principal investigator 1 ABBVIE INC. $2,567.70 01/22/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440811
Principal investigator 1 ABBVIE INC. $168.75 01/22/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440815
Principal investigator 1 ABBVIE INC. $2,894.54 01/22/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440819
Principal investigator 1 ABBVIE INC. $255.15 01/22/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440823
Principal investigator 1 ABBVIE INC. $2,894.54 01/22/2025 Non-covered Recipient Entity
PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440827